Effects of Rosuvastatin on Aortic Stenosis Progression

Launched by ASTRAZENECA · Dec 1, 2008

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Mild to moderate AS defined by peak Doppler aortic valve velocity 2.5 to 4 m/sec
• • Baseline LDL-C value must be within targeted level for all risk categories according to the Canadian Guidelines
• • Baseline triglyceride levels must be within target level for the risk categories
• Exclusion Criteria:
• • Very mild AS defined by peak Doppler AS velocity \<2.5m/sec, because the rate of progression is not well defined; Females of child bearing potential who do not practice adequate contraception.
• • Severe AS defined by peak Doppler AS velocity \> 4m/sec. These patients are excluded because they will have a high probability of aortic valve replacement even without further AS progression.
• • Greater than moderate aortic regurgitation, defined as aortic jet width to aortic outflow tract ratio \>0.45; Patients with diabetes or with a fasting blood sugar level \> 7.0 mmol/L (must be confirmed with one repeat assay within 14 days).
• • Significant concomitant mitral valve disease, defined by \> moderate mitral regurgitation (MR) or mitral valve area (MVA)\< 1.5 cm2; A very high risk of CAD (10 year risk \> 30%), according to the Canadian Guidelines.